Overview of Life Expectancy with EDS

Life expectancy in Ehlers-Danlos Syndrome (EDS) varies significantly depending on the specific subtype. For most types, such as hypermobile EDS (hEDS) and classical EDS (cEDS), life expectancy is generally normal, with patients facing chronic symptoms like pain, joint instability, and skin fragility rather than life-threatening complications. Proper management of symptoms and comorbidities ensures a good quality of life in these cases.

However, certain subtypes, particularly vascular EDS (vEDS) and kyphoscoliotic EDS (kEDS), carry heightened risks that may reduce life expectancy. Vascular EDS, characterized by fragile blood vessels and organ rupture, has a median life expectancy of approximately 48 years, with many patients experiencing critical complications by their 30s or 40s. Kyphoscoliotic EDS, which can involve respiratory and vascular issues, may also shorten lifespan in severe cases.

Early diagnosis, regular monitoring, and a multidisciplinary care approach are crucial for mitigating risks and improving outcomes across all EDS subtypes. While some forms of EDS can be life-limiting, proactive management significantly enhances both life expectancy and quality of life.

‍

Hypermobile EDS Life Expectancy is Not Reduced

Hypermobile Ehlers-Danlos Syndrome (hEDS) is the most common subtype of EDS, and it does not typically shorten life expectancy. Patients with hEDS generally have a normal lifespan, though the condition can significantly impact quality of life due to chronic symptoms such as joint instability, musculoskeletal pain, and fatigue.

While hEDS itself is not associated with life-threatening complications, comorbid conditions often seen in hEDS patients—such as the Pentad or Triad of Postural Orthostatic Tachycardia Syndrome (POTS), Mast Cell Activation Syndrome (MCAS), and gastrointestinal disorders—can increase the overall disease burden. These associated conditions may require ongoing management to maintain quality of life.

With a proactive, multidisciplinary approach, individuals with hEDS can manage their symptoms effectively and lead fulfilling lives. Though the condition presents daily challenges, life expectancy in hEDS is not significantly impacted.

‍

Lifespan in Vascular EDS (vEDS)

Life expectancy in vEDS is significantly reduced due to vascular and organ fragility. Recent data indicate a median lifespan of 51 years (49 years for males and 53 years for females), with a range from 10 to 80 years. However, this varies significantly depending on factors such as the type of COL3A1 mutation, the presence and severity of vascular and organ complications, as well as the timing and effectiveness of diagnosis and management​.

Factors that shorten lifespan include arterial ruptures, gastrointestinal perforations, delayed diagnosis, and pregnancy-related complications. Conversely, early diagnosis, use of beta-blockers like celiprolol, regular monitoring, lifestyle modifications, and patient education can extend lifespan and improve quality of life.

Factors That Shorten Lifespan in vEDS

1. Vascular Ruptures

• Primary Cause of Mortality: Arterial rupture is the leading cause of death in vEDS, occurring suddenly and often without warning.
• Age of Onset: The average age for the first major arterial or gastrointestinal complication is 23 years.
• Common Sites of Rupture: These include large arteries, such as the aorta, and medium-sized arteries in the abdomen and extremities.

2. Gastrointestinal Perforations

• Spontaneous intestinal ruptures are another leading cause of mortality, affecting about 25–30% of individuals.
• These events often require emergency surgical intervention, which can be complicated by tissue fragility.

3. Pregnancy-Related Risks

• In women with vEDS, uterine rupture during pregnancy or delivery is a major risk and can be fatal if not managed promptly.
• Pregnancy-related complications occur in about 50% of pregnancies, and approximately 5% of pregnancies result in maternal death.
• These risks are highest during the first pregnancy.

4. Delayed Diagnosis

• Many cases of vEDS go undiagnosed until a catastrophic event, such as arterial or intestinal rupture, occurs.
• This delay limits opportunities for preventative measures or early intervention.

5. Genetic Mutations

• Life expectancy is influenced by the specific COL3A1 mutation:
  • Splice site mutations leading to exon skipping result in the lowest median survival.
  • Substitutions of bulky residues (e.g., arginine, aspartic acid) for glycine residues are moderately severe.
  • Substitutions of smaller residues (e.g., alanine, serine) are less severe.
  • Null mutations delay complications by nearly two decades, and some individuals with these mutations live into their 70s or 80s.

6. Lack of Preventative Management

• Without appropriate medical supervision and lifestyle modifications, the risk of complications increases.
• Individuals unaware of their condition may engage in high-risk activities, exacerbating their vulnerability.

‍

Factors That Can Extend Lifespan in vEDS

1. Early Diagnosis and Genetic Testing

Early recognition of vEDS through genetic testing enables preventative measures and specialized care. Family screening can also identify at-risk relatives.

2. Use of Beta-Blockers

Celiprolol, a beta-blocker, has been shown to reduce the frequency of arterial events (ruptures or dissections) by up to threefold.Patients treated with celiprolol experience longer intervals between vascular events. However, celiprolol is not yet available in the United States.

3. Regular Medical Monitoring

• Close follow-up with healthcare providers experienced in managing vEDS helps with early detection and management of complications.
• Annual vascular imaging (e.g., MRA, CTA, or Doppler ultrasound) can identify issues before they become life-threatening.

4. Lifestyle Modifications

• Patients are advised to avoid activities that increase the risk of trauma or vascular strain, such as heavy lifting, contact sports, and intense exercise.
• Avoiding smoking and maintaining blood pressure in the normal range are critical to minimizing stress on blood vessels.

5. Surgical Precautions

• In cases requiring surgery, meticulous planning and techniques adapted for tissue fragility can improve outcomes.
• Emergency preparedness for addressing complications like arterial or intestinal ruptures is essential.
• Procedures such as endovascular interventions are preferred over open surgery when possible.

6. Patient Education and Emergency Preparedness

• Carrying a medical alert bracelet and emergency care documents (e.g., "vEDS passport") ensures rapid and appropriate treatment during acute events.
• Educating patients and families about warning signs (e.g., sudden pain, unexplained bruising) encourages timely medical attention.
  ‍

Lifespan in vEDS can vary widely depending on factors such as the type of COL3A1 mutation and the effectiveness of management strategies. While the condition is associated with significant mortality risks, proactive management—including genetic testing, the use of beta-blockers, regular monitoring, and patient education—can extend lifespan and improve quality of life. For individuals with vEDS, personalized care plans and expert medical oversight are critical for navigating this complex condition.

‍

Lifespan in each Type of Ehlers-Danlos Syndrome

1. Classical EDS (cEDS) – Type I and Type II

• Life Expectancy: Normal.
• Key Features:
  • Skin hyperextensibility, atrophic scarring, and joint hypermobility.
  • Increased risk of hernias and complications during wound healing.
• Risks:
  • Fragile skin and delayed healing can complicate surgeries or injuries, but these do not typically affect lifespan.
• Management:
  • Skin protection, careful surgical planning, and physical therapy to maintain joint function.

2. Classical-like EDS (clEDS)

• Life Expectancy: Normal.
• Key Features:
  • Joint hypermobility, soft skin, and spontaneous bruising without atrophic scarring.
• Risks:
  • Primarily limited to joint instability and skin bruising, with no significant life-threatening risks.
• Management:
  • Joint stabilization and protection against skin injuries.

3. Cardiac-Valvular EDS (cvEDS)

• Life Expectancy: May be reduced due to heart complications.
• Key Features:
  • Severe heart valve abnormalities, often requiring surgical intervention.
  • Skin hyperextensibility and joint issues.
• Risks:
  • Progressive cardiac valve disease may impact lifespan if untreated.
• Management:
  • Regular cardiac monitoring and timely interventions for valve repair or replacement.

4. Vascular EDS (vEDS) – Type IV

• Life Expectancy: Reduced, with a median of 48 years.
• Key Features:
  • Fragile arteries, thin translucent skin, and a high risk of spontaneous arterial or organ rupture.
  • 25% of individuals experience a significant medical event by age 20, and 80% by age 40.
• Risks:
  • Life-threatening complications such as aortic dissection or bowel rupture.
• Management:
  • Regular vascular imaging, blood pressure management, and lifestyle modifications to reduce trauma risks.

5. Hypermobile EDS (hEDS) – Type III

• Life Expectancy: Generally normal.
• Key Features:
  • Generalized joint hypermobility, chronic musculoskeletal pain, frequent joint dislocations, and subluxations.
  • Associated conditions include Postural Orthostatic Tachycardia Syndrome (POTS) and gastrointestinal issues such as irritable bowel syndrome (IBS).
• Risks:
  • Although not life-limiting, chronic pain, fatigue, and autonomic dysfunction can impact quality of life.
• Management:
  • Physical therapy for joint stability, pain management, and treatment of associated conditions.

6. Arthrochalasia EDS (aEDS) – Type VIIA and Type VIIB

• Life Expectancy: Normal.
• Key Features:
  • Congenital bilateral hip dislocation, severe joint hypermobility, and skin fragility.
  • Early-onset osteoarthritis and joint instability.
• Risks:
  • Mobility challenges and potential surgical complications.
• Management:
  • Orthopedic care, physical therapy, and supportive joint measures.

7. Dermatosparaxis EDS (dEDS) – Type VIIC

• Life Expectancy: Typically normal.
• Key Features:
  • Extreme skin fragility with sagging, redundant skin, and easy bruising.
  • Increased risk of hernias and complications during wound repair.
• Risks:
  • Fragile tissues may complicate surgeries or injuries but do not typically affect lifespan.
• Management:
  • Careful handling of skin, management of hernias, and supportive care.

8. Kyphoscoliotic EDS (kEDS) – Type VI

• Life Expectancy: Potentially reduced.
• Key Features:
  • Severe scoliosis from birth, hypotonia (reduced muscle tone), and tissue fragility.
  • Vascular complications and restrictive lung disease due to scoliosis.
• Risks:
  • Respiratory issues and vascular complications may shorten lifespan.
• Management:
  • Early intervention for scoliosis, respiratory monitoring, and physical therapy for muscle tone improvement.

9. Brittle Cornea Syndrome (BCS)

• Life Expectancy: Normal.
• Key Features:
  • Fragile corneas prone to rupture, leading to potential blindness.
• Risks: Eye injuries requiring immediate attention but no systemic life-threatening risks.
• Management: Regular ophthalmological care and protective measures for the eyes.

10. Spondylodysplastic EDS (spEDS)

• Life Expectancy: Normal.
• Key Features:
  • Short stature, muscle hypotonia, and bowing of limbs.
• Risks: Reduced mobility and skeletal complications but no life-threatening risks.
• Management: Physical therapy for strength and mobility, along with supportive care.

11. Musculocontractural EDS (mcEDS)

• Life Expectancy: Normal.
• Key Features:
  • Congenital joint contractures, skin abnormalities, and distinct facial features.
• Risks: Limited to mobility and potential joint complications.
• Management: Physical therapy and joint care.

12. Myopathic EDS (mEDS)

• Life Expectancy: Variable; normal in mild cases but may be reduced in severe forms.
• Key Features:
  • Muscle weakness, joint stiffness, and contractures.
• Risks: Severe muscle weakness may impact mobility and quality of life in advanced cases.
• Management: Tailored physical therapy and supportive care for maintaining muscle function.

13. Periodontal EDS (pEDS)

• Life Expectancy: Normal.
• Key Features:
  • Severe early-onset periodontitis, often leading to premature tooth loss (before age 30).
  • Gingival (gum) recession, fragile skin, and delayed wound healing.
  • Mild joint hypermobility and a tendency for easy bruising.
• Risks:
  • Dental infections due to poor healing in the gums.
  • Systemic inflammation from chronic periodontal disease.
• Management:
  • Specialized dental care and regular periodontal checkups.
  • Aggressive oral hygiene and use of antiseptic mouthwashes.
  • Prophylactic antibiotics before dental procedures to prevent infections.

Factors Influencing Life Expectancy in EDS

1. Subtype Severity:
   • Types like vascular EDS (vEDS) and kyphoscoliotic EDS (kEDS) pose significant mortality risks due to complications such as arterial rupture, organ failure, or respiratory issues.
   • Hypermobile EDS (hEDS) and classical EDS (cEDS) generally allow for normal lifespans but may lead to chronic pain and reduced quality of life.
2. Comorbid Conditions:
   • Dysautonomia (e.g., POTS), mast cell activation syndrome (MCAS), and gastrointestinal disorders often complicate the clinical picture, adding to the disease burden.
3. Fragile Tissues and Associated Risks:
   • Arterial or organ ruptures in vEDS.
   • Chronic joint dislocations, pain, and early-onset osteoarthritis in hEDS and cEDS.
4. Access to Multidisciplinary Care:
   • Timely interventions by specialists, including geneticists, cardiologists, physiotherapists, and pain management experts, significantly improve outcomes and quality of life.

Conclusion

The impact of Ehlers-Danlos Syndrome on life expectancy depends significantly on the specific subtype. While hypermobile (Type III) and classical (Types I and II) EDS typically allow for normal lifespans, vascular EDS (Type IV) and kyphoscoliotic EDS (Type VI) carry greater risks that may shorten life expectancy. Early diagnosis, proactive management, and access to multidisciplinary care are essential for mitigating complications and improving outcomes. By understanding the unique challenges of each subtype, patients and families can navigate the complexities of EDS with greater confidence and preparedness.

‍
FAQ: Ehlers-Danlos Syndrome (EDS) and Life Expectancy

How does Ehlers-Danlos affect lifespan?

The impact of Ehlers-Danlos Syndrome (EDS) on lifespan depends on the type of EDS. Most types, such as hypermobile (Type III) and classical (Types I and II), do not significantly affect life expectancy. However, vascular EDS (vEDS, Type IV) and kyphoscoliotic EDS (kEDS, Type VI) are associated with life-threatening complications that may shorten lifespan. Early diagnosis and proactive management are key to mitigating risks.

What is the most common cause of death in EDS?

In vascular EDS (vEDS), the most common cause of death is arterial rupture, which can lead to severe internal bleeding. Organ ruptures, such as bowel or uterine tears, are also significant risks. These complications often occur spontaneously or after minor trauma. For other types of EDS, mortality is typically not increased.

What can make EDS worse?

Certain factors can worsen symptoms of EDS:

• Physical overexertion or high-impact activities that strain joints.
• Inadequate pain management or lack of physical therapy.
• Poor posture and muscle deconditioning.
• Stress, which can exacerbate chronic pain and fatigue.
• Untreated comorbid conditions like Postural Orthostatic Tachycardia Syndrome (POTS) or gastrointestinal dysfunction.

How does EDS affect quality of life?

EDS significantly affects quality of life for many patients, especially those with chronic pain, frequent joint dislocations, or fatigue. Comorbidities such as dysautonomia, gastrointestinal issues, and mental health conditions like anxiety and depression may further impact daily functioning. Supportive care, physical therapy, and mental health support can improve quality of life.

What is the life expectancy of someone with a connective tissue disorder?

The life expectancy for individuals with connective tissue disorders varies widely depending on the condition. In most types of EDS, life expectancy is normal. However, for vascular EDS (vEDS), the median life expectancy is approximately 48 years due to the high risk of arterial or organ rupture.

Can you live a full life with a connective tissue disease?

Yes, many individuals with connective tissue disorders, including most types of EDS, live full and fulfilling lives. While challenges such as chronic pain or joint instability may require ongoing management, advancements in medical care and lifestyle adaptations help patients lead active lives.

Is EDS life-limiting?

In most types of EDS, such as hypermobile (Type III) and classical (Types I and II), life expectancy is not significantly affected, and the condition is not life-limiting. However, vascular EDS (Type IV) can be life-limiting due to the risk of arterial or organ rupture.

What can EDS do to your heart?

EDS can affect the heart in several ways:

• Patients with vascular EDS (vEDS) are at risk of arterial rupture or aneurysm, which can lead to severe cardiovascular complications.
• Cardiac-valvular EDS (cvEDS) is associated with progressive weakening of the heart valves, leading to potential valve dysfunction and complications like high blood pressure.
• Routine cardiac evaluations are recommended to monitor and manage these risks.

Has anyone died from Ehlers-Danlos Syndrome?

Yes, fatalities have occurred in certain types of EDS, particularly vascular EDS (vEDS), where arterial or organ rupture can lead to life-threatening events. These complications often arise suddenly, emphasizing the importance of early diagnosis and vigilant monitoring.

How fast does EDS progress?

The progression of EDS varies widely:

• Hypermobile EDS (hEDS) may show gradual worsening of joint instability, pain, and fatigue over time but is not inherently progressive.
• Vascular EDS (vEDS) may lead to sudden and life-threatening complications at any age, with risks increasing in adulthood.
• The rate of progression often depends on symptom management and medical interventions.

What can cvEDS do to your heart?

Patients with cardiac-valvular EDS (cvEDS) experience progressive weakening of the heart valves, leading to complications such as:

• Mitral or aortic valve dysfunction.
• High blood pressure, which can exacerbate cardiac strain.
• Regular cardiac monitoring and timely interventions, such as valve repair, are critical for managing these risks.

How long do people with vEDS typically live?

The median lifespan for individuals with vEDS is approximately 48 years.

What is the range of life expectancy for vEDS?

Life expectancy ranges from 6 to 73 years, reflecting the variability in the severity of complications and the quality of management. Sudden vascular events, such as arterial rupture, can occur even in childhood or early adulthood, while some individuals with milder presentations or effective management may live into their 70s.

What can vEDS do to your heart?

Vascular EDS (vEDS) affects the cardiovascular system by weakening blood vessels, increasing the risk of:

• Arterial rupture or aneurysm.
• Spontaneous or trauma-induced tearing of blood vessels, which can result in severe bleeding requiring emergency surgical intervention.
  Patients with vEDS require routine vascular imaging and blood pressure management to minimize risks.

What organ failure is EDS associated with?

Organ failure in EDS is most commonly linked to vascular EDS (vEDS). This type carries a high risk of rupture or failure of hollow organs, including:

• Arterial rupture leading to severe internal bleeding.
• Bowel rupture, which may cause peritonitis or sepsis.
• Uterine rupture, particularly during pregnancy.

These complications necessitate close medical supervision and emergency preparedness.

References

• Bowen, J. M., Sobey, G. J., Burrows, N. P., Colombi, M., Lavallee, M. E., Malfait, F., & Francomano, C. A. (2017). Ehlers-Danlos syndrome, classical type. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 175(1), 27–39. https://doi.org/10.1002/ajmg.c.31548
• Byers, P. H., Belmont, J., Black, J., De Backer, J., Frank, M., Jeunemaitre, X., Johnson, D., Pepin, M., Robert, L., Sanders, L., & Wheeldon, N. (2017). Diagnosis, natural history, and management in vascular Ehlers-Danlos syndrome. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 175(1), 40–47. https://doi.org/10.1002/ajmg.c.31553
• Fikree, A., Chelimsky, G., Collins, H., Kovacic, K., & Aziz, Q. (2017). Gastrointestinal involvement in the Ehlers-Danlos syndromes. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 175(1), 181–187. https://doi.org/10.1002/ajmg.c.31546
• Harris, D. (2024). The 13 types of Ehlers-Danlos syndrome. Ehlers-Danlos Syndrome (EDS). Retrieved from https://www.eds.clinic/articles/ehlers-danlos-syndrome-eds-types
• Inokuchi, R., Kurata, H., Endo, K., Kitsuta, Y., Nakajima, S., Hatamochi, A., & Yahagi, N. (2014). Vascular Ehlers-Danlos syndrome without the characteristic facial features: A case report. Medicine, 93(28), e291. https://doi.org/10.1097/MD.0000000000000291
• Harris, D. (2024). Gastrointestinal disorders in Ehlers-Danlos syndrome and POTS. Ehlers-Danlos Syndrome (EDS). Retrieved from https://www.eds.clinic/articles/gastrointestinal-disorders-in-ehlers-danlos-syndrome-and-pots
• Malfait, F., Francomano, C., Byers, P., Belmont, J., Berglund, B., Black, J., Bloom, L., Bowen, J. M., Brady, A. F., Burrows, N. P., Castori, M., Cohen, H., Colombi, M., Demirdas, S., De Backer, J., De Paepe, A., Fournel-Gigleux, S., Frank, M., Ghali, N., Giunta, C., … Tinkle, B. (2017). The 2017 international classification of the Ehlers-Danlos syndromes. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 175(1), 8–26. https://doi.org/10.1002/ajmg.c.31552

‍